1. Cancer Biology

Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer

  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti  Is a corresponding author
  1. Johns Hopkins University, United States
  2. Johns Hopkins School of Medicine, United States
  3. Stony Brook University, United States
  4. Howard Hughes Medical Institute, Ludwig Center, United States
https://doi.org/10.7554/eLife.61082
Share this article
Cite this article
  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti
(2021)
Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer
eLife 10:e61082.
https://doi.org/10.7554/eLife.61082
  2. Download BibTeX
  3. Download .RIS

Abstract

Determining the etiologic basis of the mutations that are responsible for cancer is one of the fundamental challenges in modern cancer research. Different mutational processes induce different types of DNA mutations, providing 'mutational signatures' that have led to key insights into cancer etiology. The most widely used signatures for assessing genomic data are based on unsupervised patterns that are then retrospectively correlated with certain features of cancer. We show here that supervised machine-learning techniques can identify signatures, called SuperSigs, that are more predictive than those currently available. Surprisingly, we found that aging yields different SuperSigs in different tissues, and the same is true for environmental exposures. We were able to discover SuperSigs associated with obesity, the most important lifestyle factor contributing to cancer in Western populations.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

The following previously published data sets were used
    1. Weinstein
    (2013) TCGA
    CDG @ https://portal.gdc.cancer.gov/.
    https://portal.gdc.cancer.gov/

Article and author information

Author details

  1. Bahman Afsari

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  2. Albert Kuo

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  3. YiFan Zhang

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  4. Lu Li

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  5. Kamel Lahouel

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4339-5749

  6. Ludmila Danilova

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2813-3094

  7. Alexander Favorov

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  8. Thomas A Rosenquist

    Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States
    Competing interests
    No competing interests declared.

  9. Arthur P Grollman

    Department of Pharmacological Sciences, Department of Medicine, Stony Brook University, Stony Brook, United States
    Competing interests
    No competing interests declared.

  10. Ken W Kinzler

    Howard Hughes Medical Institute, Ludwig Center, Baltimore, United States
    Competing interests
    Ken W Kinzler, K.W.K. is a founder of and hold equity, and serve as consultant to Thrive Earlier Detection and Personal Genome Diagnostics. K.W.K. is on the Board of Directors of Thrive Earlier Detection. K.W.K. is a consultant to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. K.W.K. is a consultant to and hold equity in NeoPhore. The companies named above, as well as other companies, have licensed previously described technologies from Johns Hopkins University. K.W.K is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..

  11. Leslie Cope

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  12. Bert Vogelstein

    Ludwig Center & Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    Bert Vogelstein, B.V. is a founder of and hold equity, and serve as consultant to Thrive Earlier Detection and Personal Genome Diagnostics. B.V. is a consultant to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. BV is also a consultant to Nexus, and is a consultant to and hold equity in NeoPhore. The companies named above, as well as other companies, have licensed previously described technologies from Johns Hopkins University. B.V. is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..

  13. Cristian Tomasetti

    Oncology, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    ctomasetti@jhu.edu
    Competing interests
    Cristian Tomasetti, C.T. is a consultant to Bayer and Johnson & Johnson. Thrive Earlier Detection has licensed previously described technologies from Johns Hopkins University. C.T. is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3277-4804

Funding

The John Templeton Foundation (#61471)

  • Bahman Afsari
  • Albert Kuo
  • YiFan Zhang
  • Lu Li
  • Kamel Lahouel
  • Ludmila Danilova
  • Cristian Tomasetti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Afsari et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,084
    views
  • 442
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti
(2021)
Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer
eLife 10:e61082.
https://doi.org/10.7554/eLife.61082

Share this article

https://doi.org/10.7554/eLife.61082

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    Changes in local mineral homeostasis facilitate the formation of benign and malignant testicular microcalcifications

    Ida Marie Boisen, Nadia Krarup Knudsen ... Martin Blomberg Jensen
    Research Article

    Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2. Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap, protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap/Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.

    1. Cancer Biology

    TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis

    Qianqian Ju, Wenjing Sheng ... Cheng Sun
    Research Article

    TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.

    1. Cancer Biology
    2. Cell Biology

    Breast Cancer: How cell crowding causes cancer cells to spread

    Rui Hua, Jean X Jiang
    Insight

    Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.